Next Article in Journal
Neurons, Nose, and Neurodegenerative Diseases: Olfactory Function and Cognitive Impairment
Next Article in Special Issue
Cardiomyocyte Apoptosis Is Associated with Contractile Dysfunction in Stem Cell Model of MYH7 E848G Hypertrophic Cardiomyopathy
Previous Article in Journal
Dihomo-γ-Linolenic Acid (20:3n-6)—Metabolism, Derivatives, and Potential Significance in Chronic Inflammation
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Alterations in Calcium Handling Are a Common Feature in an Arrhythmogenic Cardiomyopathy Cell Model Triggered by Desmosome Genes Loss

by
Marta Vallverdú-Prats
1,
David Carreras
1,
Guillermo J. Pérez
1,2,3,
Oscar Campuzano
1,2,3,
Ramon Brugada
1,2,3,4 and
Mireia Alcalde
1,*
1
Cardiovascular Genetics Center, Biomedical Research Institute of Girona, 17190 Salt, Spain
2
Department of Medical Sciences, Universitat de Girona, 17003 Girona, Spain
3
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 21005 Madrid, Spain
4
Hospital Josep Trueta, 17007 Girona, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(3), 2109; https://doi.org/10.3390/ijms24032109
Submission received: 15 December 2022 / Revised: 11 January 2023 / Accepted: 13 January 2023 / Published: 20 January 2023
(This article belongs to the Special Issue Molecular Research Progress of Inherited Cardiomyopathies)

Abstract

:
Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac disease characterized by fibrofatty replacement of the myocardium. Deleterious variants in desmosomal genes are the main cause of ACM and lead to common and gene-specific molecular alterations, which are not yet fully understood. This article presents the first systematic in vitro study describing gene and protein expression alterations in desmosomes, electrical conduction-related genes, and genes involved in fibrosis and adipogenesis. Moreover, molecular and functional alterations in calcium handling were also characterized. This study was performed d with HL1 cells with homozygous knockouts of three of the most frequently mutated desmosomal genes in ACM: PKP2, DSG2, and DSC2 (generated by CRISPR/Cas9). Moreover, knockout and N-truncated clones of DSP were also included. Our results showed functional alterations in calcium handling, a slower calcium re-uptake was observed in the absence of PKP2, DSG2, and DSC2, and the DSP knockout clone showed a more rapid re-uptake. We propose that the described functional alterations of the calcium handling genes may be explained by mRNA expression levels of ANK2, CASQ2, ATP2A2, RYR2, and PLN. In conclusion, the loss of desmosomal genes provokes alterations in calcium handling, potentially contributing to the development of arrhythmogenic events in ACM.

1. Introduction

Arrhythmogenic cardiomyopathy (ACM) is a rare heart disease characterized by the progressive loss of cardiomyocytes and its replacement by fibrofatty tissue. It affects the right ventricle, but biventricular and left-dominant forms predominantly have also been reported [1,2]. The principal symptoms are ventricular arrhythmias and sudden cardiac death, which are present in up to 50% of cases [3,4]. ACM affects one in 2000–5000 individuals, and it has been reported that deleterious variants of genes encoding desmosomal proteins are the main cause of ACM [5].
Desmosomes are essential for cardiomyocyte integrity because they provide cells with the ability to resist mechanical forces by joining cells together and connecting extracellular contacts with internal intermediate filaments [6]. These structures are located in intercalated discs, and they are composed of plakophilin2 (PKP2), desmoplakin (DSP), desmoglein2 (DSG2), desmocollin2 (DSC2), and plakoglobin (JUP). Pathogenic variants in any of these genes have been associated with ACM, with PKP2 the most common mutated gene in ACM patients (10–45%), followed by DSP (10–15%), DSG2 (7–10%), and DSC2 (2%) [7].
A general molecular feature of the disease is alterations in expression levels of desmosomes or genes related to electrophysiologic functions of the heart. In that sense, it has been described that electrical coupling and intercellular adhesion in the heart are connected by a functional unit called connexome, which is constituted by voltage-gated sodium channel (Nav1.5), Connexin-43 (Cx43) and desmosomes [8,9]. It is known that there is an overlapping between Brugada Syndrome and ACM due to these interactions found in the connexome [10,11].
Moreover, fibrosis and adipogenesis play an important role in ACM, with transforming growth factor beta 1 (TGFB1) and peroxisome proliferator-activated receptor gamma (PPARγ), respectively, the key genes of these pathways [12]. However, part of the pathophysiological mechanism in ACM remains to be clarified.
To date, a great number of animal and cell models with genetic alterations in desmosomal genes have been generated [12,13,14]. The HL1 cell line is one of the most preferred in vitro models due to its capacity to maintain differentiated cardiac properties at morphological, biochemical, and electrophysiological levels after several passages [15]. HL1 was generated from the AT-1 atrial cardiomyocyte tumor lineage, and it was the first ACM cell model [14].
Because of all these available models, it has been possible to identify gene-specific molecular alterations in ACM. However, not all desmosomal genes are equally studied. There are many studies describing molecular and functional consequences of the loss of PKP2, both in vitro and in vivo, but the number of studies is reduced for DSC2 or DSG2 in ACM. It is still unknown if the alterations described in PKP2, such as disruption in calcium handling [16,17,18,19] or downregulation of Cx43 expression [14,20,21], are shared by all desmosomal genes.
Our study aims to elucidate common molecular alterations triggered by the loss of desmosomal genes to unmask key factors that may be important for ACM development. Specifically, we present the first systematic study characterizing molecular alterations using a consistent in vitro model to study the main desmosomal genes. Specifically, we studied gene expression of desmosomal, calcium handling, electrical conduction, TGFB1, and PPARγ genes, and functional changes in calcium homeostasis with the loss of PKP2, DSG2, DSC2, and DSP using CRISPR-edited HL1 cell lines.

2. Results

2.1. Generation and Validation of Gene-Specific Knockout Clones PKP2, DSG2 and DSC2

The PKP2-KO, DSG2-KO, and DSC2-KO groups comprised four HL1 clones for each edited gene, PKP2, DSG2, and DSC2, respectively. All of the clones presented frameshifts leading to a premature termination codon (PTC) within the 5′ region of the three desmosomal genes studied. None of the edited clones produced detectable levels of the truncated protein (Figure S1). Genotypes of all 12 edited clones are shown in Supplementary Table S2.

2.2. Alterations in the Expression Levels of Desmosomal Genes

The expression levels of mRNA and protein of the five desmosomal genes in the PKP2-KO, DSC2-KO, and DSG2-KO groups were evaluated by RT-PCR and WB. At the mRNA level, all 12 edited clones presented undetectable expression levels of DSC2 (Figure 1A), with DSC2 downregulation as the only common feature. Additionally, gene-specific alterations were also found, depending on the knocked-out gene, with DSC2-KO the only group with no downregulation in the desmosomal genes. The relative quantifications (RQs) of the RT-PCR are shown in Table S3.
Consistently, at the protein level, DSC2 downregulation was also the only common alteration. However, other alterations were revealed. PKP2-KO clones showed undetectable levels of DSC2 and canonical DSG2 (130 KDa) and downregulated DSP and PG, with decreased levels of all desmosomal proteins (Figure 1B). Moreover, DSG2-KO clones showed decreased levels of all proteins except for DSP (Figure 1C). Finally, the only alteration in the desmosomal expression found in DSC2-KO clones was the downregulation of the DSP protein (Figure 1D). Table S4 shows the p-value of the statistical analysis of mRNA and protein expression levels of all edited clones.

2.3. Alterations in the Calcium Cycle

2.3.1. Expression Levels

To detect common alterations regarding calcium handling in the edited clones, both mRNA and protein expression levels of calcium genes known to be decreased in the absence of PKP2 [16] were studied.
At the mRNA level, all PKP2, DSG2, and DSC2 edited clones shared downregulation of ANK2, ATP2A2, and CASQ2 (Figure 2A). Gene-specific alterations were also found, with PKP2-KO the group with the greatest decrease in the calcium handling genes, showing significant downregulation in all the studied genes except for PLN. In contrast, DSC2-KO clones, apart from the shared alterations, only showed downregulation of TRDN and were the group with the least molecular alterations. Interestingly, although PLN did not show significant differences in any of the desmosomal KO groups, it exhibited a tendency of upregulation in all of them. RQs of the RT-PCR results are shown in Table S3.
At the protein level, ANK2 and RYR2 were found to be significantly downregulated in the three groups, which was a common feature among all the clones (Figure 2B). Replicates of the RYR2 WB are shown in the Supplementary Materials (Figures S2–S4). Table S4 shows the p-value of the statistical analysis of the mRNA and protein expression levels of all edited clones.

2.3.2. Calcium Imaging

Edited clones were evaluated functionally for calcium handling homeostasis. First, the characteristics of calcium transients elicited by a local pulse of caffeine (10 mM caffeine, 1 s duration) were studied. Second, the rate of the cytosolic calcium rise and the kinetics of the decay were evaluated. To this end, traces of fluorescence of a colorant over time representing cytosolic calcium transients were measured. The number of traces obtained per cell line is shown in Table S5, and the final plot representing the averaged traces of all KO groups is presented in Figure 3A.
All three KO groups presented similar kinetics but were significantly different compared to WT clones. Additionally, hierarchical statistical analysis was performed on six parameters of the calcium transient: half-width duration, rise time 10–50%, decay time 50–10%, rise time 10–90%, decay time 90–10%, and decay time 90–50% (Figure 3B, Table S6). Interestingly, all the clones presented a significantly longer half-width duration compared to WT clones, indicating a slower calcium removal. Furthermore, DSG2-KO and DSC2-KO also presented a significantly longer rise time of 10–90% and decay time of 90–50%, and only DSG2-KO showed a significantly longer decay time of 90–10% compared with WT clones. These increased times indicate both slower release and re-uptake in the KO clones DSG2 and DSC2. All values of calcium transients are shown in Table S7.

2.4. Alterations in Electrical Conduction Related Genes Cx43 and Nav1.5

Cx43 and Nav1.5 (encoded by SCN5A) expression levels were evaluated to detect possible shared alterations related to electrical functionality in the edited clones. At the mRNA level, Cx43 was downregulated in all the clones studied (Figure 4A), although only DSG2-KO showed a significantly lower expression of Cx43 protein (Figure 4B). Replicates of the CX43 WB are shown in the Supplementary Materials (Figures S2–S4). SCN5A showed downregulation only in the PKP2-KO clones at the mRNA level (Figure 4A). However, all edited clones showed undetectable levels of Nav1.5 protein. RQs of the RT-PCR are shown in Table S3. Table S4 shows the p-value of the statistical analysis of the mRNA and protein expression levels of all edited clones.

2.5. Fibrosis and Adipogenesis: Alterations in TGFB1 and PPARγ Genes

The expression levels of TGFB1 and PPARγ genes, as key factors of fibrosis and adipogenesis, were evaluated by RT-PCR. The results revealed that TGFB1 was significantly upregulated in DSG2-KO and DSC2-KO groups, while PKP2-KO showed only a tendency in the same direction (Figure 5). Table S8 shows the p-value of the statistical analysis, and the RQs of the RT-PCR are shown in Table S9. Additionally, higher levels of PPARγ were detected in PKP2-KO, DSG2-KO, and DSC2-KO groups (Table S10). RQs could not be calculated for PPARγ as no expression was detected in any of the four WT clones (cycle threshold (CT) >35 cycles, CTs mean= 36.18), while edited clones showed CT <35 cycles (PKP2-KO CT mean = 32.5, DSG2-KO CT mean = 31.06, and DSC2-KO CT mean = 33.65).

2.6. Molecular and Functional Evaluation of N-Truncated DSP and DSP-KO

The DSP-KO edited clones, in contrast to the PKP2-KO, DSC2-KO, and DSG2-KO clones, triggered the re-initiation of translation and were able to synthesize N-DSP [22]. Molecular and functional characterization of N-DSP and DSP-KO in this group was performed qualitatively as statistical analyses were not possible because one DSP-KO clone did not trigger re-initiation of translation. In contrast, the remaining clones synthesized N-DSP [22].

2.6.1. Expression Levels

mRNA levels of N-DSP and DSP-KO clones were analyzed by RT-PCR for CACNA1C and PLN, which were not included in our previous study [22]. This suggested PLN downregulation in DSP-KO (Figure 6A), in contrast to the higher PLN levels observed in PKP2-KO, DSG2-KO, and DSC2-KO clones (Figure 2A). RQs are shown in Table S11.
WB was performed for N-DSP and DSP-KO clones to analyze DSC2, ANK2, and Nav1.5 protein levels, which were undetectable for the PKP2-KO, DSG2-KO, and DSC2-KO clones and thus a possible common feature of desmosomal genes loss. From these proteins, DSP-KO clones had undetectable DSC2 levels, while N-DSP showed normal DSC2 expression (Figure 6B). However, loss of ANK2 and Nav1.5 was not observed for DSP-KO or N-DSP clones (Figure 6B). Finally, DSG2 protein levels were also studied, but none of the clones showed any change in the levels of total DSG2 (Figure 6B).

2.6.2. Calcium Imaging

Finally, a 10-mM caffeine peak was performed on N-DSP and DSP-KO clones to describe their calcium-handling homeostasis at a functional level. The number of traces per clone is shown in Table S5, and the peak is shown in Figure 7A. Both clones, N-DSP and DSP-KO, presented different kinetics compared with the other three groups evaluated (PKP2-KO, DSG2-KO, and DSC2-KO) (Figure 3A). The N-DSP peak was similar compared with the WT clones, showing an analogous amplitude. However, DSP-KO presented slightly different kinetics compared to both WT and N-DSP clones with a shorter amplitude, indicating a quicker calcium removal. Results for the six kinetic parameters are represented in Figure 7B and Table S12. All clones had similar values for all parameters with a high standard deviation. However, the half-width may have been shorter in DSP-KO compared with WT and N-DSP clones (Figure 7B, Table S12). Hierarchical statistical analysis was not performed due to the limited number of clones.

3. Discussion

ACM is an inherited cardiomyopathy mainly caused by rare pathogenic variants in genes encoding desmosomal proteins. Although there are several studies describing molecular alterations found in ACM cells and animal models, most of them are only focused on PKP2, the main gene currently associated with ACM. Few studies, including all desmosomal genes using the same technical approach, have been published so far. For this reason, the present study aimed to elucidate ACM common alterations shared by the loss of desmosomal genes. Here, we presented the first systematic in vitro study using CRISPR-edited HL1 cells to characterize gene expression profiles and functional alterations following the loss of PKP2, DSG2, DSC2, and DSP.

3.1. DSC2 Downregulation

This study revealed a dramatic downregulation of DSC2 as a common feature of the ACM cellular models, shared by all desmosomal KOs studied. These results suggested that DSC2 downregulation may be a common molecular feature of the ACM cellular phenotype. In this sense, previous studies in explanted hearts of ACM indicated the same findings, showing a general decrease of either DSC2 mRNA levels [23] or DSC2 protein levels [24]. However, the molecular mechanisms leading to this common DSC2 downregulation remain unknown, and further studies will be needed.
Interestingly, some previous studies using ACM heart samples found divergent results in desmosomal protein expression. One study described the downregulation of all desmosomal genes [25], while another only found differences in some of them [23], and a third did not find significant differences at all [24]. These discrepancies might be explained by the different causal genes of the ACM samples. Our systematic study showed downregulation of DSC2 was a common feature caused by the absence of PKP2, DSG2, DSC2, or DSP. However, it is still unclear if this alteration was also shared by different variants other than those with PTCs or by other ACM-associated genes. Moreover, here, no other common alterations in desmosomal expression genes have been described, suggesting that the downregulation of the other desmosomal genes found in the present study might be gene-specific.

3.2. Cx43 and Nav1.5 Downregulation

To date, alterations in Cx43 and Nav1.5 levels or sodium currents have been widely associated with PKP2 [14,20,21,26,27,28], or DSP [29,30,31,32] decreases or silencing, while they are quite unknown for DSG2 and DSC2. It has been reported that a null allele in DSG2 caused regional differences regarding Cx43 expression but no significant differences in the total Cx43 protein content [33]. Moreover, another publication indicated that a null mutation in DSC2 was associated with gap junction remodeling and decreased Cx43 in the intercalated discs [34]. However, only one patient was involved in that study, and possible alterations in Nav1.5 levels remain unknown for DSC2 and DSG2 mutations. Our study showed a significant downregulation of Cx43 at the transcriptional level among all PKP2-KO, DSG2-KO, and DSC2-KO clones. This downregulation was also validated at the protein level in DSG2-KO clones. At the same time, no significant differences were found for PKP2-KO and DSC2-KO clones, although our results suggested a tendency to downregulation of protein levels.
Nav1.5 protein was not detected in any of the PKP2-KO, DSG2-KO, or DSC2-KO groups, indicating that, as previously reported for PKP2 loss [26,28], the absence of DSG2 or DSC2 may also produce alterations in the sodium current. Additionally, unlike the other groups, the DSP-KO clones presented detectable levels of Nav1.5. However, our results did not determine if the total levels of Nav1.5 were significantly different from WT, as described earlier [32], because of the very limited number of DSP-KO clones.

3.3. TGFB1 and PPARγ Upregulation

Our results showed an increase in TGFB1 and PPARγ shared by the PKP2-KO, DSG2-KO, and DSC2-KO clones. Specifically, the results demonstrated that TGFB1 was significantly increased in DSG2-KO and DSC2-KO clones, suggesting that the loss of DSG2 and DSC2 could activate fibrosis. It was previously reported that the loss of PKP2 increased the expression of TGFB1 [35]. Interestingly, Dubash et al. demonstrated that it was the loss of DSP expression in a PKP2 knockdown that provoked the increased expression of TGFB1 since the rescue of DSP expression restored normal levels of TGFB1 in that model [35]. Our results of the DSC2-KO clones showed that increased levels of TGFB1 and a reduction of DSP levels were in concordance with the proposed mechanism in this previous publication. However, our results of the DSG2-KO clones also showed increased levels of TGFB1 but unaltered levels of DSP, suggesting that the TGFB1 upregulation may also occur through a DSP-loss-independent manner. More studies would be needed to elucidate the underlying mechanisms in these clones.
An increase in PPARγ expression was also shared by the PKP2-KO, DSG2-KO, and DSC2-KO groups. These results point in the same direction as previously published studies. It has been reported that the right ventricles of ACM patients expressed higher levels of PPARγ, independently of the mutated gene [36]. Furthermore, cell models with alterations in PKP2 or DSC2 also showed increased levels of PPARγ [25,37,38]. Thus, our results support the idea that increased PPARγ is a common molecular feature in the ACM cellular phenotype. It is triggered by either a PKP2, DSG2, or DSC2 loss, potentially leading to an adipogenic process.

3.4. Downregulation in Calcium Handling Gene Expression

In the last few years, a small number of studies have been published describing calcium handling gene alterations associated with a desmosomal protein loss [16,18,19,39]. Three of them were focused on the loss of PKP2, which is the most studied gene in this field. It is well described that transcription of genes involved in the calcium cycle requires PKP2 [16]. The present study characterized, for the first time, the permanent loss of different desmosomal proteins using CRISPR editing in the same in vitro model, thus avoiding differences between the selected models.
The main shared feature among PKP2-KO, DSG2-KO, and DSC2-KO clones was the dramatic downregulation of RYR2 and ANK2 proteins. Our results supported previous studies showing a significant decrease in RYR2 and ANK2 in a PKP2-KO mouse model [16,19] and also revealed these downregulations to be a common feature between PKP2 loss and cadherin (DSG2 and DSC2) loss.
Finally, the DSP-KO clones exhibited detectable levels of ANK2 protein, while the PKP2-KO, DSG2-KO, and DSC2-KO groups did not. Moreover, the shared tendency for the upregulation of PLN among the PKP2-KO, DSG2-KO, and DSC2-KO groups was remarkable, even more so given that DSP-KO showed the opposite tendency. These data together suggest that DSP loss might have different impacts on calcium handling gene expression.

3.5. Slower Re-Uptake of Calcium with PKP2, DSG2, or DSC2 Loss

Several studies have been published describing calcium cycling alterations using different in vivo and in vitro experimental approaches [16,18,39]. Our study explored these functional alterations triggered by desmosomal protein loss using, for the first time, the same in vitro system for all the main genes. Our results with PKP2-KO, DSG2-KO, and DSC2-KO clones showed similar calcium transient kinetics with a slower re-uptake of calcium with a significantly longer duration, while the DSP-KO clones presented completely different kinetics with a shorter amplitude. Our results are in concordance with previously published studies showing that the loss of PKP2 caused a delayed amplitude of the peak in a mouse model [16]. However, regarding the loss of DSG2, it was previously shown to produce a shorter amplitude of the peak in heterozygous cardiomyocytes derived from iPSC cells [39]. These discordant results may be explained by the heterozygosity of the previously reported model and the different methodology used to measure calcium transients.
Taking together the massive dysregulation of calcium handling gene expression and subsequently altered calcium transient kinetics, we hypothesized putative molecular mechanisms underlying these results. PKP2-KO, DSC2-KO, and DSG2-KO clones presented shared downregulated levels of ATP2A2, CASQ2, RYR2, and ANK2. ATP2A2 encodes SERCA2, and a decrease of this protein could be responsible for the delay in the re-uptake of calcium to the sarcoplasmic reticulum. CASQ2 encodes calsequestrin-2, which is located inside the sarcoplasmic reticulum and acts as a calcium buffer, regulating the calcium release by RYR2 [40]. Thus, the downregulation of CASQ2 and RYR2 might be the mechanism underlying the dysregulation of calcium release, shown as a significantly increased rise time in DSG2-KO and DSC2-KO clones. Interestingly, although CASQ2 and RYR2 were also downregulated in PKP2-KO, the rise time was not significantly increased in this group. For this reason, the PKP2 loss might trigger other additional mechanisms associated with these functional alterations. In this sense, it was previously published that the loss of PKP2 triggered the phosphorylation of the RYR2 T2809 residue that led to an increased sarcoplasmic reticulum calcium load and higher diastolic calcium concentration due to a function gain of RYR2 [18]. This gain of function of RYR2 could compensate for the decreased levels of RYR2 protein in PKP2-KO clones, and this may explain the unaltered rise time. Therefore, our results are compatible with this previous idea that PKP2 loss may trigger specific mechanisms related to RYR2 phosphorylation that was not found in the other desmosomal gene clones.
ANK2 was commonly downregulated in PKP2-KO, DSC2-KO, and DSG2-KO clones. This protein plays an essential role in the localization and membrane stabilization of NCX1 (encoded by SLC8A1) and SERCA2 [40]. Therefore, we hypothesize that decreased ANK2 might be involved in the delayed re-uptake of calcium because NCX1 and SERCA2 may be less efficient in returning calcium to the extracellular medium and to the sarcoplasmic reticulum, respectively. In agreement with this hypothesis, DSP-KO clones, which showed detectable levels of ANK2 protein, presented a slightly shorter amplitude in the calcium peak. Therefore, ANK2 could be causing these differences in peak amplitude in the studied clones. In fact, previous studies showed that heterozygous ANK2-KO mice presented more frequent Ca2+ sparks and waves compared with WT mice [41,42]. Ca2+ waves are caused by a higher Ca2+ content in the sarcoplasmic reticulum [43], indicating that the absence of ANK2 causes dysregulation of calcium homeostasis.
Additionally, PLN is an inhibitor of the activity of ATP2A2, decreasing SERCA affinity for calcium in its unphosphorylated state [44]. An increased expression of PLN may reduce ATP2A2 activity, producing a delay in the re-uptake of calcium into the sarcoplasmic reticulum and thus causing the delayed amplitude of the peak in PKP2-KO, DSG2-KO, and DSC2-KO clones. However, in the DSP-KO clones, downregulated levels of PLN may trigger the higher activity of ATP2A2, leading to a more rapid re-uptake of calcium to the sarcoplasmic reticulum. Therefore, changes in PLN mRNA expression levels could explain the functional alterations in all clones.
Moreover, it is important to take into account that PLN is an ACM-associated gene classified as definite by ClinGen [45]. Specifically, there are several studies of the variant PLN R14del, which is prevalent in the Netherlands. It presents a stronger affinity for SERCA2, suggesting that the inhibition of SERCA2 is higher in those patients. This equates to a risk for malignant ventricular arrhythmias [46,47,48]. Regarding its role in calcium handling, it has been shown that it causes a slower SR Ca+2 re-uptake [49]. Taking this into account, the calcium handling dysregulation underlying ACM caused by PLN R14del or by the absence of PKP2, DSG2, or DSC2 might be similar. More studies are needed in that direction to elucidate if those ACM-causal genes share molecular and functional alterations in calcium handling.
Regarding the relation between ACM clinical features and these molecular and functional detected alterations in calcium handling, it is interesting to add some related data. On the one hand, it has been observed an association between decreased SERCA2 and heart failure [50]. In that sense, it has been developed gene therapy for heart failure based on the overexpression of SERCA2. There is data that confirm its effectiveness [51,52], but, for the moment, it has not been validated in a large-scale clinical trial [53,54]. In the present study, PKP2, DSG2, and DSC2-KOs experiment with a decrease in ATPase expression (codified for SERCA), indicating that the absence of those genes may be linked to heart failure, a clinical feature present in ACM phenotype.
On the other hand, the molecular and functional detected alterations may also be related to dysregulation of the Ca2+ content, which is associated with different clinical alterations [43]. A high Ca2+ content in the SR could contribute to propagating a wave of Ca2+ induced—Ca2+ release increasing the propensity to arrhythmias, while a low Ca2+ content is associated with heart failure [43]. Our experimental approach was not able to determine the Ca2+ content of each cell line. Still, for future experiments, it would be interesting to measure it to see if there is any association between arrhythmias or heart failure with the loss of a determinate desmosomal protein via calcium handling.
Finally, our study also demonstrated that N-DSP proteins were produced by re-initiation of translation triggered by a 5′-PTC, with no major alterations in the expression profile [22], and were also revealed to be fully functional in terms of calcium handling.

4. Materials and Methods

4.1. sgRNA Design and Cloning into the Cas9 px458 Vector

The Benchling web tool (BiologySoftware, 2018; retrieved from https://benchling.com) was used to design the sgRNAs of the four desmosomal genes in the first 160 codons of the sequences for editing by CRISPR/Cas9. sgRNAs with high scores and a low off-target number were selected: PKP2 (5′-GTATGTCTACAAGCTACACG-3′, FW); DSP (5′-CCACCCGCGGATCAACACGC-3′, FW); DSG2 (5′-TGGCGCGGAGCCCGGGTGAC-3′, FW); DSC2 (5′-GCTGTGGGATCTATGCGCTCC-3′, FW). The px458 vector (plasmid #48138, Addgene, Teddington, UK), which encodes Cas9 wild-type (WT), was digested by BbsI-HF (R3539S, New England BioLabs, Ipswich, MA, USA) at 37 °C overnight and ligated by T4 DNA ligase (M0202L, New England BioLabs, Ipswich, MA, USA) for 1 h at room temperature with the sgRNA previously annealed (sense and antisense). Annealing of sgRNAs was performed with T4 PNK (M0201S, New England BioLabs, Ipswich, MA, USA) using the following thermocycler program: 30 min at 37 °C, 5 min at 95 °C, and 94 to 25 °C decreasing 1 °C per 12 s. DH5alpha competent cells (18265-017, Invitrogen, Waltham, MA, USA) were transformed with the sgRNA-px458 vector for 30 min on ice and 45 s at 42 °C. DNA was extracted using a Plasmid Midi Kit (12143, Qiagen, Hilden, Germany).

4.2. HL-1 Cell Culture and Electroporation

HL1 cells were cultured as described previously [15] at 37 °C under 5% CO2 on fibronectin-gelatin-coated slides in Claycomb medium (51800C, Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (10270106, GIBCO, Waltham, MA, USA), 100 U/mL penicillin, 10 mg/mL streptomycin (P4333-100 ML, Sigma, St Louis, MO, USA), 2 mM L-glutamine (35050061, Thermo, Waltham, MA, USA), 0.1 mM norepinephrine (A9512, Sigma, St Louis, MO, USA), and 0.3 mM ascorbic acid (A7631, Sigma, St Louis, MO, USA). Plasmids were nucleofected into HL-1 cells in suspension by using the Amaxa Cell Line Nucleofector Kit V (VCA-1003, Lonza, Basel, Switzerland); 106 cells per condition were transfected by adding 4 ug of the vector. Next, cells were seeded into 24-well plates, and after 48 h, they were diluted by seeding 10,000 cells on a P100 and 5000 cells on a 6-well plate. When colonies started growing, they were picked and seeded on a 24-well plate. Cells were expanded and frozen in a vial (with Claycomb medium and 10% dimethyl sulfoxide (D2650-5X5ML, Sigma, St Louis, MO, USA)) and a pellet to extract gDNA.

4.3. gDNA Extraction and Sanger Sequencing

To extract gDNA from the HL1 clones, QuickExtract (QE09050, Lucigen, Middleton, WI, USA) was used. For this process, 20 µL of the reagent was added to each pellet and vortexed for 13 s. Samples were incubated at 65 °C for 6 min, vortexed for 15 s, and incubated at 98°C for 2 min. Primers, PCR conditions, and kits used are listed in Supplementary Table S1. Next, ExoZap cleaning (7200100-1000, Ampliqon, Odense, Denmark) and BigDye reactions (4336911, Applied Biosystems, Waltham, MA, USA) were performed. DNA was precipitated by adding sodium acetate and 70% ethanol diluted in formamide. Samples were sequenced using a 3500 Genetic Analyzer (Applied Biosystems, Waltham, MA, USA). Sequencing Analysis Software 7 was used to analyze the sequences.

4.4. RNA Extraction and Real-Time PCR (RT-PCR)

Total RNA was purified using the RNeasy Mini Kit (74106, Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The prior reverse transcription reaction was performed with an additional step of DNase I treatment and with gDNA Wipeout buffer. Reverse transcription reactions of RNA were performed using the QuantiTect Reverse Transcription Kit (205313, Qiagen, Hilden, Germany). A final volume of 20 µL of reverse transcription reaction was obtained by mixing 1 µg of total RNA with 4 µL of RT buffer, 1 µL of primer mix, and 1 µL of reverse transcriptase in nuclease-free water. cDNA was analyzed with real-time PCR reactions using a KAPA SYBER FAST Universal Kit (KK4602, KAPA Biosystems, St Louis, MO, USA) for desmosomal, calcium handling (except CACNA1C), Cx43, and SCN5A genes. For CACNA1C, TGFB1, and PPARγ, TaqMan Fast Advanced Master Mix (4444557, Applied Biosystems, Waltham, MA, USA) was used. RPLP0 was used as a housekeeping gene for both methods, and all data were analyzed using the QuantStudio™ Real-Time PCR System and Cloud Software (ThermoFisher, Waltham, MA, USA). The obtained results were analyzed statistically using SPSS by using the Mann–Whitney U test for comparisons between two groups and the Kruskal–Wallis H test for comparison between the four groups. In all cases, it was assumed that our data was not normally distributed because there were only four cases per group.

4.5. Protein Extraction and Western Blot (WB)

Total protein was extracted by lysing the cells with 1% sodium dodecyl sulfate, incubating at 95 °C for 15 min, and vortexing for 15 min. Protein samples were quantified using a Pierce BCA Protein Assay Kit (23225, Thermo Scientific, Waltham, MA, USA) and separated in a 10% acrylamide stain-free gel (1610183, Bio-Rad, Hercules, CA, USA) using BlueStar Pre-stained Protein Marker Plus (MWPO4, Nippon Genetics, Düren, Germany) for 30 min at 80 V and 1 h at 160 V. Stain-free gels were exposed to UV light before protein transfer to activate the trihalo compound that reacted with tryptophan residues, allowing rapid fluorescent detection of total protein. Proteins were transferred from gels to polyvinylidene fluoride membranes (10600023, GE Healthcare Life Sciences, Boston, MA, USA) for 2 h at 80 V and 4 °C. The membrane was exposed to UV light to obtain a protein charge measurement to normalize the results. Membranes were blocked with phosphate-buffered saline (PBS) with 0.1% Tween and 5% non-fat milk for 1 h at room temperature and then incubated with the primary antibody anti-desmoplakin 1/2 (2722-5204, Bio-Rad, Hercules, CA, USA) at 1:500, anti-plakoglobin (13-8500, Invitrogen, Waltham, MA, USA) at 1:1000, anti-plakophilin-2 (ab189323, Abcam, Cambridge, UK) at 1:250, anti-desmoglein2 (ab150372, Abcam, Cambridge, UK) at 1:3000, anti-desmocolin-2 (AF7490, Bio-Techne RD systems, Minneapolis, MN, USA) at 1:200, anti-ryanodine receptor-2 (NBP1-19484, Novus Biologicals, Centennial, CO, USA) at 1:1000, anti-connexin-43 (C6219, Sigma, St Louis, MO, USA) at 1:4000, anti-ankiryn-2 (821501, BioLegend, San Diego, CA, USA) at 1:200, and anti-voltage-gated sodium channel 1.5 (23016-1-AP, Proteintech, Minneapolis, MN, USA) at 1:5000 overnight at 4 °C. After several PBS washes, the membranes were incubated with peroxidase-conjugated anti-rabbit antibody (111-035-003, Jackson ImmunoResearch, West Grove, PA, USA) or anti-mouse antibody (115-035-003, Jackson ImmunoResearch, West Grove, PA, USA) and anti-goat antibody (705-035-003, Jackson ImmunoResearch, West Grove, PA, USA) at a 1:10,000 dilution for 1 h at room temperature. A chemiluminescent signal was obtained with a substrate (1705061, Bio-Rad, Hercules, CA, USA) and detected using the ChemiDoc MP imaging system. Expression levels were quantified by Image Lab software using the total protein of the stain-free blots to normalize the bands [55]. The obtained results were analyzed statistically using SPSS by performing Mann–Whitney U tests only on the blots in which bands were detected in all samples. In all cases, it was assumed that our data was not a normal distribution because there were only four cases per group. The WB bar plots that were generated represented the protein levels of triplicate sample quantification, including data from the blots shown in Figure 2 and Figure 3, and Figure 5 and also for replicates shown in the Supplementary Materials (Figures S1–S3).

4.6. Calcium Imaging

HL1 cells (384 cells/mm2) were seeded on register chambers (BT-CSR1, Cell Microcontrols, Norfolk, VA, USA) 24–48 h prior to the experiments. Cells were loaded with 5 µM of Fluo4-AM (F14201, Invitrogen, Waltham, MA, USA) in the presence of 0.02% Pluronic F-127 (P2443 Sigma-Aldrich, Saint Louis, MO, USA) in NK physiological solution (140 mM NaCl, 3 mM KCl, 10 mM HEPES, 1.2 mM MgCl2, 1.8 mM CaCl2, and 10 mM glucose) for 30 min at room temperature. For the calcium transient measurements, all the solutions were maintained at 35–37 °C with a temperature controller (TC2bip, Cell Microcontrols, Norfolk, VA, USA). Calcium transients were induced by a 1-s pulse of 10 mM caffeine applied with a local perfusion pipette (MPRE8, Cell Microcontrols, Norfolk, VA, USA). Calcium transients were recorded at 32 fps using an inverted microscope (Nikon Eclipse Ti, Japan) equipped with an electron-multiplying CCD camera (Hamamatsu C900-13, Hamamatsu, Japan) and a fast illumination system (Lambda DG4, Sutter Instrument, Novato, CA, USA). The acquisition was controlled from a personal computer with MetaFluor Imaging System software (Molecular Devices, Sunnyvale, CA, USA). Peak parameters were measured with Clampfit 10.2 (Molecular Devices, Sunnyvale, CA, USA), and a hierarchical statistical analysis was performed with a Ratonly RStudio script following the criteria described previously [56].

5. Conclusions

This study presented the first systematic in vitro study using CRISPR-edited HL1 cells to define common molecular and functional effects of PKP2, DSG2, DSC2, and DSP loss using the same experimental approach.
Our study revealed that DSC2 downregulation was the only common alteration in desmosomal expression genes shared by the absence of PKP2, DSG2, DSC2, or DSP. Interestingly, PKP2 loss triggered major alterations in desmosomal and calcium-handling gene expression. Regarding electrical conduction alterations, PKP2, DSG2, and DSC2-KO caused the downregulation of Nav1.5, but this was not shared by DSP-KO. Moreover, upregulation of TFGB1 and PPARγ was also found to be a common molecular feature for PKP2, DSG2, and DSC2 loss, although no data was available for the loss of DSP.
Finally, our results showed massive dysregulation in calcium handling genes shared by PKP2, DSC2, or DSG2 loss associated with a slower calcium re-uptake that might be related to the ANK2, CASQ2, ATP2A2, and RYR2 decrease or PLN increase. In contrast, DSP-KO clones produced a shorter amplitude of the calcium peak, which might be associated with the downregulation of PLN, which was only shown in DSP-KO clones. More studies would be needed to corroborate these associations. Moreover, the present study demonstrated that N-DSP proteins are fully functional in terms of calcium cycling.
Taking all the above into account, it would be interesting for future studies to investigate deeply the calcium handling alterations caused by the absence of desmosomal genes. After seeing the presented results in that direction, describing the association between ACM clinical features, such as arrhythmia or heart failure, and the causal gene explained by alterations of calcium handling would clarify the molecular pathophysiology of the disease. Moreover, we have proposed several molecular alterations in calcium handling that could explain the functional dysregulation. Still, more studies are needed to confirm those associations and the cause-consequence relation. Targeting the genes whose altered expression levels are the cause of presenting a shorter or delayed amplitude of the calcium peak could be useful to start searching for a treatment to compensate for the calcium handling alterations and maybe to avoid an important part of arrhythmogenic features.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24032109/s1.

Author Contributions

Conceptualization, M.V.-P. and M.A.; methodology, M.V.-P. and D.C.; software, M.V.-P. and D.C.; validation, M.V.-P., D.C., G.J.P., O.C. and M.A.; formal analysis, M.V.-P.; investigation, M.V.-P., D.C. and M.A.; resources, R.B.; data curation, M.V.-P. and M.A.; writing—original draft preparation, M.V.-P. and M.A.; writing—review and editing, D.C., G.J.P., O.C. and R.B.; visualization, M.V.-P. and M.A.; supervision, G.J.P., R.B. and M.A.; project administration, R.B. and M.A.; funding acquisition, R.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Obra Social “La Caixa Foundation” (ID:100010434) and Fondo de Investigación Sanitaria (FIS, PI22/00422).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Corrado, D.; Basso, C.; Judge, D.P. Arrhythmogenic Cardiomyopathy. Circ. Res. 2017, 121, 784–802. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. He, J.; Xu, J.; Li, G.; Zhou, D.; Li, S.; Zhuang, B.; Chen, X.; Duan, X.; Li, L.; Fan, X.; et al. Arrhythmogenic Left Ventricular Cardiomyopathy: A Clinical and CMR Study. Sci. Rep. 2020, 10, 533. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Dalal, D.; James, C.; Tichnell, C.; Calkins, H. Arrhythmogenic Right Ventricular Dysplasia: A United States Experience. Heart Rhythm 2005, 2, S115. [Google Scholar] [CrossRef]
  4. Hoorntje, E.T.; te Rijdt, W.P.; James, C.A.; Pilichou, K.; Basso, C.; Judge, D.P.; Bezzina, C.R.; van Tintelen, J.P. Arrhythmogenic Cardiomyopathy: Pathology, Genetics, and Concepts in Pathogenesis. Cardiovasc. Res. 2017, 113, 1521–1531. [Google Scholar] [CrossRef] [Green Version]
  5. Mattesi, G.; Zorzi, A.; Corrado, D.; Cipriani, A. Natural History of Arrhythmogenic Cardiomyopathy. J. Clin. Med. 2020, 9, 878. [Google Scholar] [CrossRef] [Green Version]
  6. Najor, N.A. Desmosomes in Human Disease. Annu. Rev. Pathol. Mech. Dis. 2018, 13, 51–70. [Google Scholar] [CrossRef]
  7. Corrado, D.; Van Tintelen, P.J.; McKenna, W.J.; Hauer, R.N.; Anastastakis, A.; Asimaki, A.; Calkins, H. Arrhythmogenic Right Ventricular Cardiomyopathy: Evaluation of the Current Diagnostic Criteria and Differential Diagnosis. Eur. Heart J. 2020, 41, 1414–1427. [Google Scholar] [CrossRef] [Green Version]
  8. Vermij, S.H.; Abriel, H.; van Veen, T.A.B. Refining the Molecular Organization of the Cardiac Intercalated Disc. Cardiovasc. Res. 2017, 113, 259–275. [Google Scholar] [CrossRef]
  9. Wilson, A.J.; Schoenauer, R.; Ehler, E.; Agarkova, I.; Bennett, P.M. Cardiomyocyte Growth and Sarcomerogenesis at the Intercalated Disc. Cell. Mol. Life Sci. 2014, 71, 165–181. [Google Scholar] [CrossRef] [Green Version]
  10. Ben-Haim, Y.; Asimaki, A.; Behr, E.R. Brugada Syndrome and Arrhythmogenic Cardiomyopathy: Overlapping Disorders of the Connexome? EP Eur. 2021, 23, 653–664. [Google Scholar] [CrossRef]
  11. Agullo-Pascual, E.; Cerrone, M.; Delmar, M. Arrhythmogenic Cardiomyopathy and Brugada Syndrome: Diseases of the Connexome. FEBS Lett. 2014, 588, 1322–1330. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Austin, K.M.; Trembley, M.A.; Chandler, S.F.; Sanders, S.P.; Saffitz, J.E.; Abrams, D.J.; Pu, W.T. Molecular Mechanisms of Arrhythmogenic Cardiomyopathy. Nat. Rev. Cardiol. 2019, 16, 519–537. [Google Scholar] [CrossRef] [PubMed]
  13. Gerull, B.; Brodehl, A. Genetic Animal Models for Arrhythmogenic Cardiomyopathy. Front. Physiol. 2020, 11, 624. [Google Scholar] [CrossRef] [PubMed]
  14. Sommariva, E.; Stadiotti, I.; Perrucci, G.L.; Tondo, C.; Pompilio, G. Cell Models of Arrhythmogenic Cardiomyopathy: Advances and Opportunities. Dis. Model. Mech. 2017, 10, 823–835. [Google Scholar] [CrossRef] [Green Version]
  15. Claycomb, W.C.; Lanson, N.A.; Stallworth, B.S.; Egeland, D.B.; Delcarpio, J.B.; Bahinski, A.; Izzo, N.J. HL-1 Cells: A Cardiac Muscle Cell Line That Contracts and Retains Phenotypic Characteristics of the Adult Cardiomyocyte. Proc. Natl. Acad. Sci. USA 1998, 95, 2979–2984. [Google Scholar] [CrossRef] [Green Version]
  16. Cerrone, M.; Montnach, J.; Lin, X.; Zhao, Y.-T.; Zhang, M.; Agullo-Pascual, E.; Leo-Macias, A.; Alvarado, F.J.; Dolgalev, I.; Karathanos, T.V.; et al. Plakophilin-2 Is Required for Transcription of Genes That Control Calcium Cycling and Cardiac Rhythm. Nat. Commun. 2017, 8, 106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Lyon, A.; van Opbergen, C.J.M.; Delmar, M.; Heijman, J.; van Veen, T.A.B. In Silico Identification of Disrupted Myocardial Calcium Homeostasis as Proarrhythmic Trigger in Arrhythmogenic Cardiomyopathy. Front. Physiol. 2021, 12, 732573. [Google Scholar] [CrossRef]
  18. Kim, J.-C.; Pérez-Hernández, M.; Alvarado, F.J.; Maurya, S.R.; Montnach, J.; Yin, Y.; Zhang, M.; Lin, X.; Vasquez, C.; Heguy, A.; et al. Disruption of Ca 2+i Homeostasis and Connexin 43 Hemichannel Function in the Right Ventricle Precedes Overt Arrhythmogenic Cardiomyopathy in Plakophilin-2–Deficient Mice. Circulation 2019, 140, 1015–1030. [Google Scholar] [CrossRef]
  19. van Opbergen, C.J.M.; Noorman, M.; Pfenniger, A.; Copier, J.S.; Vermij, S.H.; Li, Z.; van der Nagel, R.; Zhang, M.; de Bakker, J.M.T.; Glass, A.M.; et al. Plakophilin-2 Haploinsufficiency Causes Calcium Handling Deficits and Modulates the Cardiac Response Towards Stress. Int. J. Mol. Sci. 2019, 20, 4076. [Google Scholar] [CrossRef] [Green Version]
  20. Oxford, E.M.; Musa, H.; Maass, K.; Coombs, W.; Taffet, S.M.; Delmar, M. Connexin43 Remodeling Caused by Inhibition of Plakophilin-2 Expression in Cardiac Cells. Circ. Res. 2007, 101, 703–711. [Google Scholar] [CrossRef] [Green Version]
  21. Fidler, L.M.; Wilson, G.J.; Liu, F.; Cui, X.; Scherer, S.W.; Taylor, G.P.; Hamilton, R.M. Abnormal Connexin43 in Arrhythmogenic Right Ventricular Cardiomyopathy Caused by Plakophilin-2 Mutations. J. Cell. Mol. Med. 2009, 13, 4219–4228. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Vallverdú-Prats, M.; Brugada, R.; Alcalde, M. Premature Termination Codon in 5′ Region of Desmoplakin and Plakoglobin Genes May Escape Nonsense-Mediated Decay through the Reinitiation of Translation. Int. J. Mol. Sci. 2022, 23, 656. [Google Scholar] [CrossRef] [PubMed]
  23. Vite, A.; Gandjbakhch, E.; Prost, C.; Fressart, V.; Fouret, P.; Neyroud, N.; Gary, F.; Donal, E.; Varnous, S.; Fontaine, G.; et al. Desmosomal Cadherins Are Decreased in Explanted Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patient Hearts. PLoS ONE 2013, 8, e75082. [Google Scholar] [CrossRef] [PubMed]
  24. Akdis, D.; Medeiros-Domingo, A.; Gaertner-Rommel, A.; Kast, J.I.; Enseleit, F.; Bode, P.; Klingel, K.; Kandolf, R.; Renois, F.; Andreoletti, L.; et al. Myocardial Expression Profiles of Candidate Molecules in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia Compared to Those with Dilated Cardiomyopathy and Healthy Controls. Heart Rhythm 2016, 13, 731–741. [Google Scholar] [CrossRef] [Green Version]
  25. Chen, S.N.; Gurha, P.; Lombardi, R.; Ruggiero, A.; Willerson, J.T.; Marian, A.J. The Hippo Pathway Is Activated and Is a Causal Mechanism for Adipogenesis in Arrhythmogenic Cardiomyopathy. Circ. Res. 2014, 114, 454–468. [Google Scholar] [CrossRef]
  26. Cerrone, M.; Lin, X.; Zhang, M.; Agullo-Pascual, E.; Pfenniger, A.; Chkourko Gusky, H.; Novelli, V.; Kim, C.; Tirasawadichai, T.; Judge, D.P.; et al. Missense Mutations in Plakophilin-2 Cause Sodium Current Deficit and Associate With a Brugada Syndrome Phenotype. Circulation 2014, 129, 1092–1103. [Google Scholar] [CrossRef] [Green Version]
  27. Khudiakov, A.; Zaytseva, A.; Perepelina, K.; Smolina, N.; Pervunina, T.; Vasichkina, E.; Karpushev, A.; Tomilin, A.; Malashicheva, A.; Kostareva, A. Sodium Current Abnormalities and Deregulation of Wnt/β-Catenin Signaling in IPSC-Derived Cardiomyocytes Generated from Patient with Arrhythmogenic Cardiomyopathy Harboring Compound Genetic Variants in Plakophilin 2 Gene. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2020, 1866, 165915. [Google Scholar] [CrossRef]
  28. Sato, P.Y.; Musa, H.; Coombs, W.; Guerrero-Serna, G.; Patino, G.A.; Taffet, S.M.; Isom, L.L.; Delmar, M. Loss of Plakophilin-2 Expression Leads to Decreased Sodium Current and Slower Conduction Velocity in Cultured Cardiac Myocytes. Circ. Res. 2009, 105, 523–526. [Google Scholar] [CrossRef] [Green Version]
  29. Zhang, Q.; Deng, C.; Rao, F.; Modi, R.M.; Zhu, J.; Liu, X.; Mai, L.; Tan, H.; Yu, X.; Lin, Q.; et al. Silencing of Desmoplakin Decreases Connexin43/Nav1.5 Expression and Sodium Current in HL-1 Cardiomyocytes. Mol. Med. Rep. 2013, 8, 780–786. [Google Scholar] [CrossRef] [Green Version]
  30. Kam, C.Y.; Dubash, A.D.; Magistrati, E.; Polo, S.; Satchell, K.J.F.; Sheikh, F.; Lampe, P.D.; Green, K.J. Desmoplakin Maintains Gap Junctions by Inhibiting Ras/MAPK and Lysosomal Degradation of Connexin-43. J. Cell Biol. 2018, 217, 3219–3235. [Google Scholar] [CrossRef] [Green Version]
  31. Patel, D.M.; Dubash, A.D.; Kreitzer, G.; Green, K.J. Disease Mutations in Desmoplakin Inhibit Cx43 Membrane Targeting Mediated by Desmoplakin–EB1 Interactions. J. Cell Biol. 2014, 206, 779–797. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Gomes, J.; Finlay, M.; Ahmed, A.K.; Ciaccio, E.J.; Asimaki, A.; Saffitz, J.E.; Quarta, G.; Nobles, M.; Syrris, P.; Chaubey, S.; et al. Electrophysiological Abnormalities Precede Overt Structural Changes in Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in Desmoplakin-A Combined Murine and Human Study. Eur. Heart J. 2012, 33, 1942–1953. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Gehmlich, K.; Syrris, P.; Reimann, M.; Asimaki, A.; Ehler, E.; Evans, A.; Quarta, G.; Pantazis, A.; Saffitz, J.E.; McKenna, W.J. Molecular Changes in the Heart of a Severe Case of Arrhythmogenic Right Ventricular Cardiomyopathy Caused by a Desmoglein-2 Null Allele. Cardiovasc. Pathol. 2012, 21, 275–282. [Google Scholar] [CrossRef] [PubMed]
  34. Gehmlich, K.; Syrris, P.; Peskett, E.; Evans, A.; Ehler, E.; Asimaki, A.; Anastasakis, A.; Tsatsopoulou, A.; Vouliotis, A.-I.; Stefanadis, C.; et al. Mechanistic Insights into Arrhythmogenic Right Ventricular Cardiomyopathy Caused by Desmocollin-2 Mutations. Cardiovasc. Res. 2011, 90, 77–87. [Google Scholar] [CrossRef] [Green Version]
  35. Dubash, A.D.; Kam, C.Y.; Aguado, B.A.; Patel, D.M.; Delmar, M.; Shea, L.D.; Green, K.J. Plakophilin-2 Loss Promotes TGF-Β1/P38 MAPK-Dependent Fibrotic Gene Expression in Cardiomyocytes. J. Cell Biol. 2016, 212, 425–438. [Google Scholar] [CrossRef] [Green Version]
  36. Djouadi, F.; Lecarpentier, Y.; Hebert, J.-L.; Charron, P.; Bastin, J.; Coirault, C. A Potential Link between Peroxisome Proliferator-Activated Receptor Signalling and the Pathogenesis of Arrhythmogenic Right Ventricular Cardiomyopathy. Cardiovasc. Res. 2009, 84, 83–90. [Google Scholar] [CrossRef] [Green Version]
  37. Caspi, O.; Huber, I.; Gepstein, A.; Arbel, G.; Maizels, L.; Boulos, M.; Gepstein, L. Modeling of Arrhythmogenic Right Ventricular Cardiomyopathy With Human Induced Pluripotent Stem Cells. Circ. Cardiovasc. Genet. 2013, 6, 557–568. [Google Scholar] [CrossRef] [Green Version]
  38. Reisqs, J.; Moreau, A.; Charrabi, A.; Sleiman, Y.; Meli, A.C.; Millat, G.; Briand, V.; Beauverger, P.; Richard, S.; Chevalier, P. The PPARγ Pathway Determines Electrophysiological Remodelling and Arrhythmia Risks in DSC2 Arrhythmogenic Cardiomyopathy. Clin. Transl. Med. 2022, 12, 10765. [Google Scholar] [CrossRef]
  39. Hawthorne, R.N.; Blazeski, A.; Lowenthal, J.; Kannan, S.; Teuben, R.; DiSilvestre, D.; Morrissette-McAlmon, J.; Saffitz, J.E.; Boheler, K.R.; James, C.A.; et al. Altered Electrical, Biomolecular, and Immunologic Phenotypes in a Novel Patient-Derived Stem Cell Model of Desmoglein-2 Mutant ARVC. J. Clin. Med. 2021, 10, 3061. [Google Scholar] [CrossRef]
  40. The UniProt Consortium; Bateman, A.; Martin, M.-J.; Orchard, S.; Magrane, M.; Agivetova, R.; Ahmad, S.; Alpi, E.; Bowler-Barnett, E.H.; Britto, R.; et al. UniProt: The Universal Protein Knowledgebase in 2021. Nucleic Acids Res. 2021, 49, D480–D489. [Google Scholar] [CrossRef]
  41. Camors, E.; Mohler, P.J.; Bers, D.M.; Despa, S. Ankyrin-B Reduction Enhances Ca Spark-Mediated SR Ca Release Promoting Cardiac Myocyte Arrhythmic Activity. J. Mol. Cell. Cardiol. 2012, 52, 1240–1248. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Skogestad, J.; Aronsen, J.M.; Tovsrud, N.; Wanichawan, P.; Hougen, K.; Stokke, M.K.; Carlson, C.R.; Sjaastad, I.; Sejersted, O.M.; Swift, F. Coupling of the Na+/K+-ATPase to Ankyrin B Controls Na+/Ca2+ Exchanger Activity in Cardiomyocytes. Cardiovasc. Res. 2020, 116, 78–90. [Google Scholar] [CrossRef] [PubMed]
  43. Eisner, D. Calcium in the Heart: From Physiology to Disease: Calcium in the Heart: From Physiology to Disease. Exp. Physiol. 2014, 99, 1273–1282. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Eisner, D.A.; Caldwell, J.L.; Kistamás, K.; Trafford, A.W. Calcium and Excitation-Contraction Coupling in the Heart. Circ. Res. 2017, 121, 181–195. [Google Scholar] [CrossRef]
  45. Rehm, H.L. ClinGen—The Clinical Genome Resource. N. Engl. J. Med. 2015, 372, 2235–2242. [Google Scholar] [CrossRef] [Green Version]
  46. Haghighi, K.; Kolokathis, F.; Gramolini, A.O.; Waggoner, J.R.; Pater, L.; Lynch, R.A.; Fan, G.-C.; Tsiapras, D.; Parekh, R.R.; Dorn, G.W.; et al. A Mutation in the Human Phospholamban Gene, Deleting Arginine 14, Results in Lethal, Hereditary Cardiomyopathy. Proc. Natl. Acad. Sci. USA 2006, 103, 1388–1393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Vostrikov, V.V.; Soller, K.J.; Ha, K.N.; Gopinath, T.; Veglia, G. Effects of Naturally Occurring Arginine 14 Deletion on Phospholamban Conformational Dynamics and Membrane Interactions. Biochim. Biophys. Acta (BBA) Biomembr. 2015, 1848, 315–322. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Karakikes, I.; Stillitano, F.; Nonnenmacher, M.; Tzimas, C.; Sanoudou, D.; Termglinchan, V.; Kong, C.-W.; Rushing, S.; Hansen, J.; Ceholski, D.; et al. Correction of Human Phospholamban R14del Mutation Associated with Cardiomyopathy Using Targeted Nucleases and Combination Therapy. Nat. Commun. 2015, 6, 6955. [Google Scholar] [CrossRef] [Green Version]
  49. Kamel, S.M.; van Opbergen, C.J.M.; Koopman, C.D.; Verkerk, A.O.; Boukens, B.J.D.; de Jonge, B.; Onderwater, Y.L.; van Alebeek, E.; Chocron, S.; Polidoro Pontalti, C.; et al. Istaroxime Treatment Ameliorates Calcium Dysregulation in a Zebrafish Model of Phospholamban R14del Cardiomyopathy. Nat. Commun. 2021, 12, 7151. [Google Scholar] [CrossRef] [PubMed]
  50. Zhihao, L.; Jingyu, N.; Lan, L.; Michael, S.; Rui, G.; Xiyun, B.; Xiaozhi, L.; Guanwei, F. SERCA2a: A Key Protein in the Ca2+ Cycle of the Heart Failure. Heart Fail. Rev. 2020, 25, 523–535. [Google Scholar] [CrossRef]
  51. Jaski, B.E.; Jessup, M.L.; Mancini, D.M.; Cappola, T.P.; Pauly, D.F.; Greenberg, B.; Borow, K.; Dittrich, H.; Zsebo, K.M.; Hajjar, R.J. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical Trial. J. Card. Fail. 2009, 15, 171–181. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Jessup, M.; Greenberg, B.; Mancini, D.; Cappola, T.; Pauly, D.F.; Jaski, B.; Yaroshinsky, A.; Zsebo, K.M.; Dittrich, H.; Hajjar, R.J. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca 2+ -ATPase in Patients With Advanced Heart Failure. Circulation 2011, 124, 304–313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Greenberg, B.; Yaroshinsky, A.; Zsebo, K.M.; Butler, J.; Felker, G.M.; Voors, A.A.; Rudy, J.J.; Wagner, K.; Hajjar, R.J. Design of a Phase 2b Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Advanced Heart Failure. JACC: Heart Fail. 2014, 2, 84–92. [Google Scholar] [CrossRef]
  54. Hulot, J.-S.; Salem, J.-E.; Redheuil, A.; Collet, J.-P.; Varnous, S.; Jourdain, P.; Logeart, D.; Gandjbakhch, E.; Bernard, C.; Hatem, S.N.; et al. Effect of Intracoronary Administration of AAV1/SERCA2a on Ventricular Remodelling in Patients with Advanced Systolic Heart Failure: Results from the AGENT-HF Randomized Phase 2 Trial: SERCA2a Gene Therapy in Heart Failure. Eur. J. Heart Fail. 2017, 19, 1534–1541. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Image Lab Software. Bio-Rad. Available online: https://www.bio-rad.com/es-es/product/image-lab-software?ID=KRE6P5E8Z (accessed on 1 June 2022).
  56. Sikkel, M.B.; Francis, D.P.; Howard, J.; Gordon, F.; Rowlands, C.; Peters, N.S.; Lyon, A.R.; Harding, S.E.; MacLeod, K.T. Hierarchical Statistical Techniques Are Necessary to Draw Reliable Conclusions from Analysis of Isolated Cardiomyocyte Studies. Cardiovasc. Res. 2017, 113, 1743–1752. [Google Scholar] [CrossRef] [Green Version]
Figure 1. Desmosomal expression levels of mRNA (A) and protein of the edited clones PKP2-KO (B), DSG2-KO (C), and DSC2-KO (D). * Indicates the gene expression levels that were significantly different between WT and edited clones; p-value < 0.05, see Table S4. Number of experiments: RT-PCR = 1; WB = 3.
Figure 1. Desmosomal expression levels of mRNA (A) and protein of the edited clones PKP2-KO (B), DSG2-KO (C), and DSC2-KO (D). * Indicates the gene expression levels that were significantly different between WT and edited clones; p-value < 0.05, see Table S4. Number of experiments: RT-PCR = 1; WB = 3.
Ijms 24 02109 g001
Figure 2. Calcium cycle gene expression at the mRNA (A) and protein (B) levels. * Indicates the gene expression levels that were significantly different between WT and edited clones; p-value <0.05, see Table S4. Number of experiments: RT-PCR = 1; WB = 3.
Figure 2. Calcium cycle gene expression at the mRNA (A) and protein (B) levels. * Indicates the gene expression levels that were significantly different between WT and edited clones; p-value <0.05, see Table S4. Number of experiments: RT-PCR = 1; WB = 3.
Ijms 24 02109 g002
Figure 3. Calcium imaging peaks (A) and studied parameters (B) of the three KO groups: PKP2-KO, DSG2-KO, and DSC2-KO. The black arrow in section A indicates the pulse of caffeine. * Indicates parameters that were significantly different compared with WT clones; p-value < 0.05, see Table S6.
Figure 3. Calcium imaging peaks (A) and studied parameters (B) of the three KO groups: PKP2-KO, DSG2-KO, and DSC2-KO. The black arrow in section A indicates the pulse of caffeine. * Indicates parameters that were significantly different compared with WT clones; p-value < 0.05, see Table S6.
Ijms 24 02109 g003
Figure 4. Cx43 and SCN5A expression at the mRNA (A) and protein (B) levels of the three KO groups PKP2-KO, DSG2-KO, and DSC2-KO. * Indicates parameters that were significantly different compared with WT clones; p-value < 0.05, see Table S4. Number of experiments: RT-PCR = 1; WB = 3.
Figure 4. Cx43 and SCN5A expression at the mRNA (A) and protein (B) levels of the three KO groups PKP2-KO, DSG2-KO, and DSC2-KO. * Indicates parameters that were significantly different compared with WT clones; p-value < 0.05, see Table S4. Number of experiments: RT-PCR = 1; WB = 3.
Ijms 24 02109 g004
Figure 5. mRNA expression levels of several genes involved in ACM molecular pathways in the edited clones. * Indicates gene expression levels that were significantly different compared with WT clones; p-value < 0.05, see Table S8. Number of experiments: RT-PCR = 1.
Figure 5. mRNA expression levels of several genes involved in ACM molecular pathways in the edited clones. * Indicates gene expression levels that were significantly different compared with WT clones; p-value < 0.05, see Table S8. Number of experiments: RT-PCR = 1.
Ijms 24 02109 g005
Figure 6. mRNA expression levels of CACNA1C and PLN (A) and protein levels of DSC2, ANK2, Nav1.5, and DSG2 (B) in DSP clones. Number of experiments: RT-PCR = 1; WB = 1.
Figure 6. mRNA expression levels of CACNA1C and PLN (A) and protein levels of DSC2, ANK2, Nav1.5, and DSG2 (B) in DSP clones. Number of experiments: RT-PCR = 1; WB = 1.
Ijms 24 02109 g006
Figure 7. Calcium imaging peaks (A) and studied parameters (B) of the DSP clones. The black arrow in section A indicates the pulse of caffeine.
Figure 7. Calcium imaging peaks (A) and studied parameters (B) of the DSP clones. The black arrow in section A indicates the pulse of caffeine.
Ijms 24 02109 g007
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Vallverdú-Prats, M.; Carreras, D.; Pérez, G.J.; Campuzano, O.; Brugada, R.; Alcalde, M. Alterations in Calcium Handling Are a Common Feature in an Arrhythmogenic Cardiomyopathy Cell Model Triggered by Desmosome Genes Loss. Int. J. Mol. Sci. 2023, 24, 2109. https://doi.org/10.3390/ijms24032109

AMA Style

Vallverdú-Prats M, Carreras D, Pérez GJ, Campuzano O, Brugada R, Alcalde M. Alterations in Calcium Handling Are a Common Feature in an Arrhythmogenic Cardiomyopathy Cell Model Triggered by Desmosome Genes Loss. International Journal of Molecular Sciences. 2023; 24(3):2109. https://doi.org/10.3390/ijms24032109

Chicago/Turabian Style

Vallverdú-Prats, Marta, David Carreras, Guillermo J. Pérez, Oscar Campuzano, Ramon Brugada, and Mireia Alcalde. 2023. "Alterations in Calcium Handling Are a Common Feature in an Arrhythmogenic Cardiomyopathy Cell Model Triggered by Desmosome Genes Loss" International Journal of Molecular Sciences 24, no. 3: 2109. https://doi.org/10.3390/ijms24032109

APA Style

Vallverdú-Prats, M., Carreras, D., Pérez, G. J., Campuzano, O., Brugada, R., & Alcalde, M. (2023). Alterations in Calcium Handling Are a Common Feature in an Arrhythmogenic Cardiomyopathy Cell Model Triggered by Desmosome Genes Loss. International Journal of Molecular Sciences, 24(3), 2109. https://doi.org/10.3390/ijms24032109

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop